Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The ESMO World Congress on Gastrointestinal Cancer represents the year’s premier gathering of international oncology professionals who are dedicated to improving the lives of patients impacted by malignancies of the GI tract.

ESMO WCGIC 2022

ESMO World Congress On Gastrointestinal Cancer 2022
29 Jun–02 July 2022 | Barcelona, Spain, and Online

ESMO WCGIC 2022

ESMO World Congress On Gastrointestinal Cancer 2022
29 Jun–02 July 2022 | Barcelona, Spain, and Online
The ESMO World Congress on Gastrointestinal Cancer represents the year’s premier gathering of international oncology professionals who are dedicated to improving the lives of patients impacted by malignancies of the GI tract.
Treatments for HER2+ esophagogastric cancer 2:15
Treatments for HER2+ esophagogastric cancer
Per Pfeiffer • 27 Jun 2022
Standard-of-care for adjuvant treatment of colon cancer 1:54
Standard-of-care for adjuvant treatment of colon cancer
Julien Taieb • 29 Jun 2022
How can we use ctDNA to improve adjuvant treatment for colon cancer? 2:30
How can we use ctDNA to improve adjuvant treatment for colon cancer?
Julien Taieb • 29 Jun 2022
Challenges to be overcome in the use of ctDNA for colon cancer treatment 2:05
Challenges to be overcome in the use of ctDNA for colon cancer treatment
Julien Taieb • 29 Jun 2022
Promising future for cholangiocarcinoma diagnosis and treatment 2:11
Promising future for cholangiocarcinoma diagnosis and treatment
Lorenza Rimassa • 28 Jun 2022
DELIVER trial: Blood based biomarker analysis of patients with gastric cancer treated with nivolumab 7:38
DELIVER trial: Blood based biomarker analysis of patients with gastric cancer treated with nivolumab
Hisato Kawakami • 5 Jul 2022
Therapeutic challenges for cholangiocarcinoma 2:51
Therapeutic challenges for cholangiocarcinoma
Lorenza Rimassa • 28 Jun 2022
Highlights from ESMO WCGIC 2022 0:56
Highlights from ESMO WCGIC 2022
John Strickler • 1 Jul 2022
MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer 2:28
MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer
John Strickler • 1 Jul 2022
MOUNTAINEER-03: tucatinib plus trastuzumab plus FOLFOX for first-line treatment of mCRC 0:46
MOUNTAINEER-03: tucatinib plus trastuzumab plus FOLFOX for first-line treatment of mCRC
John Strickler • 1 Jul 2022
Treatment landscape for cholangiocarcinoma 7:22
Treatment landscape for cholangiocarcinoma
Lorenza Rimassa • 28 Jun 2022
Targeted therapies for patients with HER2+ colorectal cancer 1:19
Targeted therapies for patients with HER2+ colorectal cancer
John Strickler • 1 Jul 2022
Diagnostic challenges for cholangiocarcinoma 6:57
Diagnostic challenges for cholangiocarcinoma
Lorenza Rimassa • 28 Jun 2022
The content of VJOncology is intended for healthcare professionals